Parminder K. Judge

Old Road Campus, Roosevelt Drive
Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes: Observations from EMPA-KIDNEY.

Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes: Observations from EMPA-KIDNEY.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 15, 2026

Hierarchical Composite End Points: The Future of Randomized Trials of Kidney Disease?

Hierarchical Composite End Points: The Future of Randomized Trials of Kidney Disease?

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: April 10, 2026

Performance of estimated glomerular filtration rate equations across ethnic groups in the AIM CKD UK cohort: a multicentre cross-sectional study.

Performance of estimated glomerular filtration rate equations across ethnic groups in the AIM CKD UK cohort: a multicentre cross-sectional study.

Journal: The Lancet regional health. Europe

Published: April 03, 2026

Prospective Study of Multiparametric Renal MRI for CKD Progression (AFiRM).

Prospective Study of Multiparametric Renal MRI for CKD Progression (AFiRM).

Journal: Kidney international reports

Published: February 16, 2026

Effects of Sacubitril/Valsartan versus Irbesartan on Urine Tubular Biomarkers in Chronic Kidney Disease: Findings from the UK HARP-III Trial.

Effects of Sacubitril/Valsartan versus Irbesartan on Urine Tubular Biomarkers in Chronic Kidney Disease: Findings from the UK HARP-III Trial.

Journal: American journal of nephrology

Published: January 26, 2026

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Journal: Cardiovascular diabetology

Published: January 26, 2026

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: August 27, 2025

Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.

Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.

Journal: Kidney international reports

Published: June 19, 2025

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: June 18, 2025

Chronic kidney disease.

Chronic kidney disease.

Journal: Lancet (London, England)

Published: June 05, 2025

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Journal: The lancet. Diabetes & endocrinology

Published: May 09, 2025

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Journal: EClinicalMedicine

Published: February 18, 2025

Showing 1-12 of 40

Last Updated: 09/26/2026